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Abstract 
Background: Therapy for multiple myeloma (MM) has substantially improved in the era of 
immunomodulatory drugs and bortezomib. However, the prognosis of patients with progres-
sive disease despite treatment with these ‘novel agents’ remains poor. Recently, pomalido-
mide was approved in this setting, but a median progression-free survival of <4 months still 
leaves room for improvement. Pomalidomide-based combination therapies are currently 
under investigation, but data on long-term treatment are lacking. Case Report: We present 
the case of a 68-year-old woman with refractory MM who received pomalidomide in combi-
nation with various drugs including anthracyclines, alkylators and proteasome inhibitors. 
Initially, major hematological toxicities and infectious complications including a hepatitis B 
virus reactivation were encountered. With careful dose adjustments and selection of combi-
nation partners, pomalidomide treatment was maintained for over 4 years and led to a sus-
tained partial remission. In particular, the well-tolerated regimen of bortezomib, cyclophos-
phamide and dexamethasone together with pomalidomide was administered for >30 cycles. 
Conclusion: This case illustrates the value of an individualized approach to myeloma care 
given an increasing availability of ‘novel agents’. Tailored treatment using these drugs as a 
backbone is essential to achieve long-lasting responses and minimize side effects. 
© 2015 S. Karger AG, Basel 
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Introduction 
Immunomodulatory drugs (IMiDs) are a distinct group of oral antineoplastic drugs that 
have gained therapeutic relevance for the treatment of multiple myeloma (MM) since the 
turn of the millennium [1]. For myeloma patients, the introduction of IMiDs has fundamen-
tally changed treatment options and has significantly improved clinical outcomes [2]. How-
ever, in patients failing to respond to treatment with novel agents – including thalidomide 
and lenalidomide as well as bortezomib – treatment options are limited and survival rates 
are poor [3]. 
Pomalidomide (CC-4047), the most recent IMiD, has shown substantial clinical activity 
in this setting. A randomized phase 2 study showed that the efficacy of pomalidomide is sig-
nificantly enhanced by concomitant administration of dexamethasone and, moreover, con-
tinuous administration of the drug is well tolerated [4]. The MM-003 trial [5] demonstrated 
a significant increase in progression-free survival for patients receiving pomalidomide plus 
low-dose dexamethasone compared to patients treated with high-dose dexamethasone 
alone. The trial eventually led to the approval of pomalidomide for the treatment of patients 
with refractory and/or relapsed myeloma by the European Medicines Agency (EMA) in Au-
gust 2013. Combination protocols with bortezomib, carfilzomib, doxorubicin and oral cyclo-
phosphamide are currently under investigation, but data on the long-term treatment with 
such regimens are lacking. 
In this report, we discuss the case of a heavily pretreated female patient with refractory 
MM who received >30 cycles of an experimental combination of pomalidomide, bortezomib, 
cyclophosphamide and dexamethasone as ninth-line therapy, resulting in a long-lasting par-
tial remission (PR) and in a good quality of life. 
Case Presentation 
A 59-year-old woman was diagnosed with IgG kappa MM in May 2002, when she pre-
sented with Durie-Salmon stage III A disease with lytic destruction of the pelvis. Fluores-
cence in situ hybridization (FISH) performed on a bone marrow aspirate in 2006 did not 
reveal any high-risk cytogenetic abnormalities. Induction therapy with vincristine/doxo-
rubicin/dexamethasone was followed by double autologous stem cell transplantation after 
conditioning with high-dose melphalan (200 mg/m²), resulting in a PR that lasted for 2 
years. At first relapse, 4 cycles of bortezomib and subsequent bortezomib maintenance were 
administered and led to a PR for further 3 years. Third-line treatment with lenalidomide, 
bendamustine and dexamethasone produced only a short-lived response. Therapeutic at-
tempts with the Hsp-90 inhibitor AUY-922 (phase I-Ib/II study) and bortezomib/dexa-
methasone resulted in disease progression. Salvage treatment using multidrug combinations 
of two novel agents (bortezomib plus lenalidomide), alkylating agents (cyclophosphamide or 
melphalan) and dexamethasone also failed to induce a durable response. With high-grade 
plasma cell infiltration of the bone marrow (fig. 1), increasingly severe pancytopenia devel-
oped, causing chronic fatigue and impaired quality of life and eventually led to treatment 
discontinuation. 
In August 2010, at the age of 68 and 8 years after primary diagnosis (fig. 2), we started 
treatment with pomalidomide (4 mg days 1–21 of a 28-day cycle) and low-dose dexame-
thasone (40 mg weekly) in combination with doxorubicin (4 mg days 1–4 by continuous 
infusion). Due to grade 3 thrombocytopenia, the pomalidomide dose was reduced to 2 mg 
from cycle 2 onwards, resulting in improved tolerability, serological PR and hematological 
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improvement. However, myeloma therapy had to be stopped after six cycles due to the reac-
tivation of a hepatitis B virus (HBV) infection (11.7 × 106 copies/ml), which the patient sup-
posedly acquired in 1945 and which had never emerged during therapy before. Antiviral 
treatment with entecavir was initiated, which led to a sufficient drop in viral load (9.7 × 102 
copies/ml). 
Five months after the interruption of antimyeloma treatment, the patient suffered from 
serological disease progression and a pathological humeral fracture requiring surgical 
treatment (fig. 3). To prevent further disease progression, one more cycle of pomalido-
mide/doxorubicin/dexamethasone was administered. For the subsequent cycles, doxorubi-
cin was replaced by bendamustine (40 mg/m2 days 1–2) in light of the published data re-
porting an increased risk of HBV reactivation in patients receiving anthracyclines. However, 
two cycles of the new combination regimen resulted in transfusion-dependent anemia and 
grade 3 neutropenia, and only stable disease was observed. 
Since the patient was not eligible for treatment within one of the active clinical trials at 
our institution, individualized therapy was initiated, whereby pomalidomide (2 mg on days 
1–21 of a 28-day cycle) was combined with bortezomib (1.3 mg/m2 day 1, 4), cyclophos-
phamide (250 mg days 1–3) and dexamethasone (10 mg days 1–3, weekly thereafter). As 
ninth-line therapy, this individualized combination regimen inhibited the progression of the 
bone lesions, and the patient continued to experience a good quality of life. When the symp-
toms of sensory polyneuropathy worsened after 18 cycles, bortezomib was reduced to 1.0 
mg/m2 and the cycle length was extended to 43 days. Neuropathy improved gradually; how-
ever, we observed a steady rise in serologic disease activity. For the subsequent cycles, the 
pomalidomide dose was increased to 3 mg days 1–21 and the cycles were repeated on day 
29, resulting in sustained PR. Due to an extended treatment-free interval after 34 cycles of 
pomalidomide + VCD (bortezomib/cyclophosphamide/dexamethasone), we observed an 
increase of serologic markers. More than 12 years after primary diagnosis and 4 years and 4 
months after the first treatment with pomalidomide, regrettably, our patient succumbed to a 
fulminant pneumogenic septicemia in grade 1 neutropenia. 
Discussion 
Recently, pomalidomide was approved by the EMA for treatment of advanced MM in 
conjunction with low-dose dexamethasone based on favorable results of a phase III trial [5]. 
Even though this combination results in further disease control in heavily pretreated mye-
loma patients, the median gain in the overall survival of roughly 4 months is modest. Triplets 
of IMiDs, corticosteroids and the first-in-class proteasome inhibitor bortezomib have proven 
to be effective in various myeloma settings. Therefore, it is tempting to speculate that com-
bining pomalidomide with bortezomib and dexamethasone might be more efficacious than 
pomalidomide and dexamethasone alone. 
Eight years after initial diagnosis and following five lines of treatment, the patient in this 
report had been refractory to multidrug regimens containing both bortezomib and lenalid-
omide in combination with alkylating agents and dexamethasone. Having exhausted thera-
peutic options and with an increasing need for treatment, the idea of re-intensification using 
pomalidomide and dexamethasone as a backbone was intriguing. 
Combinations of IMiDs and doxorubicin have previously shown promising clinical activi-
ty with an acceptable toxicity profile in advanced MM [6]. Preliminary results from an ongo-
ing phase I/II study suggest that using pomalidomide together with anthracyclines and dex-
amethasone is feasible but carries the risk of substantial hematotoxicity [7]. Similarly, in our 
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patient, grade 3 thrombocytopenia was observed after treatment with pomalidomide at 
4 mg together with doxorubicin and dexamethasone. Following a pomalidomide dose reduc-
tion to 2 mg, the combination was well tolerated and resulted in a rapid serological response 
and hematologic improvement. 
Interestingly, a HBV reactivation occurred after six cycles of pomalidomide/doxo-
rubicin/dexamethasone treatment in our patient with an initially unknown HBV carrier sta-
tus. This had not been observed after previous administration of highly immunosuppressive 
high-dose melphalan prior to autologous stem cell transplantation [8]. Whilst there are clini-
cal [9] and preclinical [10] data indicating an increased risk of HBV reactivation for doxoru-
bicin-containing treatments, the role of IMiDs remains unclear [11]. Furthermore, severe 
immune dysfunction associated with advanced myeloma might also have predisposed our 
patient to virus reactivation [12]. 
With MM being a disease characterized by intraclonal heterogeneity [13] and with novel 
agents generally having bearable side effects, the use of combination regimens of three or 
more drugs, even in the advanced disease setting, becomes more and more enticing. There-
fore, we combined pomalidomide/dexamethasone with bortezomib and cyclophosphamide 
instead of doxorubicin and were able to elicit a long-lasting partial response in this heavily 
pre-treated refractory patient. Thus, it is tempting to speculate that in a progressive disease 
setting, substituting various drugs within combination treatments might help in regaining 
disease control. 
Besides the known hematological toxicities [14] that were observed at the maximum 
tolerated dose (MTD) of 4 mg, pomalidomide proved to be well tolerated in our patient for 
more than 4 years of therapy. This is in line with recently published data from a French trial 
[15] in which 12% of the patients were still on treatment with pomalidomide/dexa-
methasone after 30 months. Similarly, pomalidomide-based combination regimens appear 
to be suitable for long-term continuous application as illustrated in our case study. Tailored 
treatment approaches including careful dose adaptations are essential to control side effects 
and allow a good quality of life.  
Unfortunately, the fact of an insufficient disease control after a prolonged treatment-free 
interval made our patient more susceptible to formerly well-controlled hematological side 
effects, resulting in neutropenia and a fulminant pneumogenic septicemia. Despite intensive 
antiinfective treatment, the patient succumbed to the generalized infection shortly after 
hospitalization. 
Results from systematic trials of combination regimens containing pomalidomide are 
expected in the near future, further helping to guide therapeutic decisions in the setting of 
advanced MM. In the meantime, the use of pomalidomide/dexamethasone as a backbone in 
antimyeloma combination treatment has proven to be effective in a heavily pretreated re-
fractory patient and has demonstrated a good long-term tolerability. 
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Fig. 1. Cytomorphology of a bone marrow aspirate smear (×63) performed in August 2010 showing high-
grade diffuse infiltration with atypical plasma cells. 
 
 
 
Fig. 2. Disease course based on M protein levels indicated in months after primary diagnosis (DX). 
Benda = Bendamustine; Len = lenalidomide; Dex = dexamethasone; Bort = bortezomib; Cyclo = cyclo-
phosphamide; Mel = melphalan; Poma = pomalidomide; VCD = bortezomib/cyclophosphamide/dexa-
methasone. 
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Fig. 3. Radiograph of a pathological humeral fracture corresponding to serological disease progression in 
June 2011. Imaging after osteosynthesis with a proximally and distally fixed intramedullary nail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
